Novel Opipramol-Baclofen Combination Alleviates Depression and Craving and Facilitates Recovery From Substance Use Disorder—An Animal Model and a Human Study

Novel Opipramol-Baclofen Combination Alleviates Depression and Craving and Facilitates Recovery From Substance Use Disorder—An Animal Model and a Human Study

Substance use disorders (SUDs) are associated with depression and anxiety, with the latter being one of the major factors in substance-seeking and relapse. Due to dose-dependent sedative side effects there is limited efficacy of baclofen treatment for SUDs. Here we suggest the use of a novel combina...

Full description

Bibliographic Details
Main Authors: Ahdoot, H.L (Author), Bareli, T. (Author), Barnea, R. (Author), Ben Moshe, H. (Author), Gispan, I. (Author), Maayan, R. (Author), Rosca, P. (Author), Warhaftig, G. (Author), Weizman, A. (Author), Yadid, G. (Author)
Format: Article
Language:English
Published: Frontiers Media S.A. 2021
Subjects:
addiction
adult
animal experiment
animal model
animal tissue
anxiety disorder
Article
baclofen
clinical article
cocaine
comorbidity
controlled study
depression
double blind procedure
drug craving
drug dependence
drug detoxification
drug megadose
female
human
hydrocortisone
long term care
low drug dose
male
mood disorder
multiple drug abuse
nonhuman
nucleus accumbens
opipramol
pilot study
placebo
prasterone sulfate
protein expression level
psychological extinction
rat
recurrence risk
saliva analysis
sedation
signal transduction
stress
substance-induced depressive disorder
therapeutic center
treatment
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items